Gentian Diagnostics renews long term faecal calprotectin partnership with Bühlmann Laboratories

20. Apr 2026 | 2 min read

Moss, 20 April 2026

Gentian Diagnostics, a fast-growing developer and manufacturer of high-quality diagnostic assays, is pleased to announce the renewal of its long-term supply agreement with Bühlmann Laboratories for faecal calprotectin. Under the renewed agreement, Gentian will continue to supply key materials for Bühlmann Laboratories market-leading faecal calprotectin assay, fCAL Turbo®. 

The renewal underscores the strength of the long standing collaboration between Gentian and Bühlmann Laboratories and reflects a shared commitment to advancing faecal calprotectin testing to support improved diagnosis and monitoring of inflammatory bowel disease.

Matti Heinonen, CEO of Gentian Diagnostics ASA, commented: “We are very pleased to extend our partnership with Bühlmann Laboratories. Bühlmann has proven to be a strong partner with a continued commitment to developing the faecal calprotectin market. This agreement provides a solid foundation for long term value creation for both companies.”

Christian Eberle, CEO of Bühlmann Laboratories AG, stated: “This new agreement with our long standing partner Gentian ensures continuity and provides a strong foundation for our collaboration going forward.” 

For further information, please contact: 
Njaal Kind, CFO 
njaal.kind@gentian.no
+47 919 06 525 

About Gentian Diagnostics 
Gentian Diagnostics (OSE: GENT) develops and manufactures high-quality in vitro diagnostic reagents. Our mission is to improve diagnostic efficiency to support better treatment decisions. Gentian’s expertise and focus lie in immunoassays, specifically within infections, inflammation, kidney disease, and heart failure. By converting existing, clinically relevant biomarkers to the most efficient high throughput analysers, the company contributes to cost savings and helps protect lives. Gentian Diagnostics is headquartered in Moss, Norway, and serves the global human and veterinary diagnostics markets through sales and representative offices in Sweden, the USA, and China. For more information, please visit www.gentian.com.

You may also read


May 06, 2026 - Ole Sørlie

Gentian Diagnostics: First quarter 2026 report

Moss, 6 May 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests,..

May 06, 2026 - Ole Sørlie

Gentian Diagnostics ASA terminates NT-proBNP assay development

Moss, 6 May 2026 Following a comprehensive review of performance data and market dynamics, Gentian..

May 06, 2026 - Ole Sørlie

Gentian Diagnostics: Ex dividend NOK 0.60 today

Moss, 6 May 2026 The shares in Gentian Diagnostics ASA will be traded ex dividend NOK 0.60 as of today. The..